Fulgent Genetics Posts Mixed 2025 Results Amid Strategic Shifts
Event summary
- Fulgent Genetics reported $322.7M in 2025 revenue, up 14% YoY, but posted a GAAP loss of $60.5M.
- Q4 2025 revenue grew 9% YoY to $83.3M, with a GAAP loss of $23.4M.
- Company expects 2026 revenue of $350M but forecasts a non-GAAP loss of $1.45 per share.
- Fulgent completed acquisitions of Bako and Strata Dx, spending $56M.
- Therapeutic pipeline advances: FID-007 in Phase 2, FID-022 in Phase 1.
The big picture
Fulgent Genetics is navigating a strategic pivot from diagnostics to precision medicine, investing heavily in AI, digital pathology, and therapeutics. The company's 2025 results reflect operational improvements but also highlight execution risks tied to customer concentration and acquisition integration. With $685M in cash reserves, Fulgent has financial flexibility but must demonstrate sustained revenue growth amid shifting market dynamics.
What we're watching
- Revenue Risk
- How Fulgent offsets the impact of its largest customer moving work in-house.
- Integration Challenges
- The pace at which Bako and Strata Dx acquisitions deliver expected benefits.
- Therapeutic Pipeline
- Whether Phase 2 and Phase 1 candidates meet clinical milestones.
Related topics